

ID	Research Ethics Committee Reference Number (REC)	Integrated Research Application System Number (IRAS)	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected & Date Site Confirmed	Duration between Date Site Confirmed & First Participant Recruited	Duration between Date Site Selected & First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
122689	17/LO/0825	223457	MUSC 33570 GISST Sjorgens	Yes	20/02/2018	26	134	160	05/07/2017	13/09/2017	30/06/2017	05/07/2017	09/10/2017	09/10/2017	J - Other	First patient recruited 20/02/2018 - Under 10 total target so low recruiting study. Local R&D confirmation delayed due to Site staffing issues - number of staff involved in R&D site set-up left & on sickness leave.	NHS Provider
122690	16/EM/0380	198726	Study 15 - A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine	Yes	24/05/2018	72	216	288	09/08/2017	09/08/2017	09/11/2016	20/10/2017	20/10/2017	20/10/2017	J - Other	Study target is 4 so not required to adhere to RTT metrics. Patients are being screened for study currently.	Neither
122691	17/NE/0080	212034	Optimising neonatal service provision for preterm babies (27-31 weeks) - OPTI-PREM	Yes	14/03/2018	165	20	185	06/09/2017	10/09/2017	30/03/2017	22/02/2018	22/02/2018	22/02/2018	J - Other	No delays.	Neither
122692	16/LO/0436	162098	APRICOT_V1	No		96			04/12/2017	23/11/2017	05/07/2016	26/02/2018	27/02/2018	27/02/2018	J - Other	Green light never issued by sponsor. Pharmacy delayed SIV due to lack of availability. PI was on leave during the course of site set-up. Pharmacy raised issues with prescriptions after site opened to recruitment, which delayed recruitment. 2 patients screened for study, 1 ineligible and 1 to be approached soon.	Both
122693	17/NE/0339	214254	The CLEAR Trial	No		98			20/12/2017	20/12/2017	06/02/2018	22/02/2018	28/03/2018	18/07/2018	J - Other	Sponsors were not ready to open until late February, CTA not signed by Sponsors until early March. Green light issued on 18/07/2018 following issues with faulty trial equipment sent through. Screening has now started.	Sponsor
122696	15/LO/1576	177719	TRACC	No		79			12/01/2018	15/01/2018	06/06/2016	23/03/2018	04/04/2018	30/04/2018	J - Other	Original document pack sent through incomplete, end of March partially executed CTA received shortly before Easter bank holiday. Green light not issued until 30/04/2018. 3 patients screened but not eligible, no eligible patients to date.	Both
122697	17/WM/0079	217388	SPIT	Yes	19/06/2018	48	36	84	13/11/2017	27/03/2018	06/03/2017	10/05/2018	14/05/2018	01/06/2018	J - Other	Trial contact on leave from 30/04/2018 to 09/05/2018. Delay in signatures obtained at site.	Both
122698	17/LO/2106	232512	DALES	Yes	26/06/2018	13	5	18	08/06/2018	08/06/2018	30/01/2018	05/06/2018	21/06/2018	25/06/2018	J - Other	No delays.	Neither
123957	17/WM/0250	228393	AZ SPOCS	No		121			18/09/2017	05/12/2017	08/08/2017	27/03/2018	05/04/2018	23/04/2018	D - Sponsor Delays Other	Communication from IQVIA CRA delayed set-up process between mid-September 2017 to late-March 2018. No patients recruited as of yet - one patient screened and approached.	Sponsor
123958	17/LO/1127	227441	DISTINCT - A Study of Dinutuximab and Irinotecan for Small Cell Lung Cancer	No		4			07/11/2017	23/02/2018	31/08/2017	28/02/2018	27/02/2018	28/02/2018	J - Other	No delays in set-up. 2 patients screened, 1 ineligible due to stringent eligibility criteria, 1 approached awaiting decision from patient.	Neither
123959	18/YH/0012	237184	LEO / ECZTRA 3 ((ECZema TRAlokinumab trial no. 3)	No		56			19/12/2017	01/03/2018	14/02/2018	26/04/2018	26/04/2018	20/07/2018	D - Sponsor Delays F - No patients seen H - Contracting delays J - Other	Errors in Contract delayed set-up. Final version of contract received late April 2018. IT issues delayed green light. Screening now commenced.	Both